To assess the prognostic relevance of CARF in lymphoma, we further analyzed the additional tumor parameters, including mutation burden and chromosome structural variations.[27] Results revealed that tumor patients with high CARF expression tend to have lower mutation burden, both for non‐silent mutations (p < 0.05) and silent mutations (p < 0.001) (Figure S9, Supporting Information). This evidence concerns the gene CARF and lymphoma.